Organization Overview
Alternative names
autologous lung cancer specific T cells (1 trial)
bi-4scar cd19/22 t cells (1 trial)
bi-4scar cd19/70 t cells (1 trial)
bi-4scar cd19/79b t cells (1 trial)
bi-4scar gd2/cd56 t cells (1 trial)
bi-4scar gd2/cd70 t cells (1 trial)
bi-4scar gd2/psma t cells (1 trial)
cd44v6-specific car gene-engineered t cells (1 trial)
cervical cancer-specific car-t cells (1 trial)
cervical cancer specific engineered immune effectors (1 trial)
cmv/adv /ebv/bkv specific t cells (1 trial)
gbm-specific car-igt cells (1 trial)
gd2, psma and cd276 car-t cells (1 trial)
lv-smenp-dc vaccine and antigen-specific ctls (1 trial)
muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells (1 trial)
multiple sarcoma-specific car-t cells (1 trial)
ovarian cancer specific cytotoxic lymphocytes (1 trial)
personalized neoantigen vaccine (2 trials)
sarcoma-specific car-t cells (1 trial)
Acute Disease (Phase 1)
Adenoviridae Infections (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Communicable Diseases (Phase 2)
Cytomegalovirus Infections (Phase 2)
Disease (Phase 1)
Epstein-Barr Virus Infections (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Hemophilia A (Phase 2)
Hemophilia B (Phase 1)
Infections (Phase 2)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Multiple Myeloma (Phase 2)
Mycoses (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neuroblastoma (Phase 2)
Opportunistic Infections (Phase 2)
Ovarian Neoplasms (Phase 2)
Papilloma (Phase 2)
Preleukemia (Phase 1)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Tuberculosis (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)